Skip to content

ESWT for UE Pain in Patients With Cervical Spinal Cord Injury

The Effects of Extracorporeal Shockwave Therapy (ESWT) for Upper Extremity Pain Related to Spasticity in Patients With Spinal Cord Injury

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04319679
Enrollment
4
Registered
2020-03-24
Start date
2020-06-05
Completion date
2021-04-13
Last updated
2021-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelopathy Cervical, Pain, Spastic Tetraplegia

Keywords

Extracorporeal shockwave therapy, Cervical myelopathy, Spasticity, Pain

Brief summary

This study aimed to investigate the efficacy and safety of extracorporeal shockwave therapy (ESWT) for upper extremity pain related to spasticity in patients with spinal cord injury.

Detailed description

6 times of ESWT (3,000 pulses per time, low energy under 0.3 mJ/m\^2, tolerable range) on forearm area to reduce pain related to spasticity in patients with cervical myelopathy

Interventions

DEVICEExtracorporeal shockwave therapy

6 times during 2 weeks

DEVICESham therapy

6 times during 2 weeks

Sponsors

Bundang CHA Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Spinal cord damage confirmed in the spinal cord image 2. 1 month after spinal cord injury 3. Spasticity of upper extremities 4. Pain in areas below spinal cord injury more than 4 points on the numerical scale (NRS) 5. Cognitive functions that can clearly point out NRS with more than 15 points in the mini mental state examination (MMSE) 6. Age: 20 and older 7. Person who has agreed in writing to decide his or her participation and comply with the precautions

Exclusion criteria

1. Pain due to trauma 2. Injection treatments two weeks before participating in the study 3. Severe coagulopathy (excluding antiplatelet use) 4. Impaired cognition

Design outcomes

Primary

MeasureTime frameDescription
Numerical rating scale (NRS)Up to 4 weeks (baseline, after each treatment during 2 weeks, 2 weeks + 1 day, 4 weeks)Pain intensity (0-10, ordinal scale)

Secondary

MeasureTime frameDescription
Modified Ashworth scale (MAS)Up to 4 weeks (baseline, after each treatment during 2 weeks, 2 weeks + 1 day, 4 weeks)Spasticity, ordinal scale (0, 1, 1+, 2, 3, 4: higher scores indicate more severe spasticity)
Range of motion (ROM)Up to 4 weeks (baseline, 1 week, 2 weeks, 2 weeks + 1 day, 4 weeks)Passive ROM of elbow, wrist and 3rd finger (in degrees: higher scores indicate larger range)
Grasp powerUp to 4 weeks (baseline, 2 weeks, 4 weeks)Hand grip power (in Kg measured by a dynamometer: higher scores indicate stronger power)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026